Eli Lilly’s fourth-quarter results exceeded expectations, with revenue reaching $19.3 billion and earnings per share at $7.54. The company’s GLP-1 drugs, Mounjaro and Zepbound, performed exceptionally well, with combined sales exceeding $1 billion and showing triple-digit growth. Eli Lilly is now a leader in the GLP-1 market both domestically and internationally.

CEO David Ricks stated that Eli Lilly’s weight-loss and diabetes drugs are in high demand due to significant weight loss benefits and fewer side effects compared to competitors. CFO Lucas Montarce mentioned that Zepbound and Mounjaro have captured significant market share in the U.S., with potential for further growth.

Eli Lilly’s GLP-1 drugs have a large addressable market, with significant growth potential. The company’s patent on tirzepatide extends into the back half of the 2030s, providing a solid foundation for continued success. Plans for an oral GLP-1 drug and increased manufacturing capacity further support future growth.

Management’s guidance for the full year includes revenue estimates of $80 to $83 billion, a “performance margin” of 46% to 47.5%, and earnings of $33.50 to $35 per share. With a strong outlook and continued growth prospects, Eli Lilly remains a solid investment opportunity in the pharmaceutical industry.

Read more at CNBC: We’re raising our price target on Eli Lilly as the GLP-1 leader delivers